SEHK:3933Pharmaceuticals
Could United Laboratories (SEHK:3933) Leverage TUL01101’s Trial Success to Strengthen Its Innovation Edge?
United Laboratories International Holdings recently reported the completion of a Phase II clinical trial in China for TUL01101 Tablets, targeting adult patients with moderate-to-severe atopic dermatitis, and noted significant efficacy and favorable safety results across all tested doses.
The rapid reduction in eczema severity as early as the first week highlights the investigational drug's potential to address an unmet clinical need in dermatology.
Let's explore how the robust efficacy...